Price Chart

Executive Summary

Curis Inc. shareholders approved a charter amendment at the May 19, 2026 annual meeting to nearly double authorized common shares from 283.8M to 567.5M, providing substantial future dilution capacity. Simultaneously, the company eliminated the Certificate of Designations for its Series A and B Preferred Stock, returning those shares to undesignated authorized preferred status. For a micro-cap biotech with a ~$19M market cap, the massive authorized share increase signals potential future capital raises, but no immediate offering is announced.

Key Facts

• Authorized common shares increased from 283,757,150 to 567,514,300 (near-doubling).
• Total authorized capital stock increased from 288,757,150 to 572,514,300 shares.
• Series A and Series B Preferred Stock certificate of designations eliminated; preferred shares returned to undesignated authorized status.
• All proposals at the Annual Meeting passed, including director elections, executive compensation (non-binding), auditor ratification, and the share increase.
• Series B Preferred Stock (20,195 shares) had been auto-converted to common and pre-funded warrants in March 2026.
• Current market cap is ~$19M; the company is a pre-revenue clinical-stage biotech.

Financial Impact

Authorized common shares nearly doubled to 567.5M shares; no immediate pricing or offering attached. The company now has capacity to issue over 280M additional shares.

Risk Factors

• Substantial future dilution from the ~284M newly authorized but unissued common shares.
• Potential near-term equity financing given micro-cap capitalization and clinical-stage pipeline needs.
• No revenue disclosed; cash runway not stated — financing likely needed for operations.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status